Thus, Sphk2 does not play a role in chronic Dex-induced lipid disorders and S1PR2’s role in mediating chronic Dex-induced hypertriglyceridemia and hepatic steatosis likely does not require Sphk2. Here, S1PR2 is linked to fatty liver disease.